Related Experiment Video
Updated: Jun 25, 2025
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.2K
Glycan Structures in Osteosarcoma as Targets for Lectin-Based Chimeric Antigen Receptor Immunotherapy
Nele Prasse1, Charlotte Wessolowski1, Ingo Müller1,2
1Research Institute Children's Cancer Center Hamburg, 20251 Hamburg, Germany.
International Journal of Molecular Sciences
|May 25, 2024
Summary
Researchers explored CD301 ligands as targets for osteosarcoma immunotherapy. This lectin-based approach showed potential for treating bone cancer, especially when combined with immune checkpoint inhibitors like TIGIT.
Area of Science:
- Immunology
- Oncology
- Glycobiology
Background:
- Osteosarcoma affects children and young adults, with poor survival rates for relapsed or metastatic cases.
- Current treatments have limited efficacy for advanced osteosarcoma.
- Targeting specific molecular structures on cancer cells is a promising immunotherapy strategy.
Purpose of the Study:
- To investigate CD301 ligands as potential targets for osteosarcoma immunotherapy.
- To evaluate the efficacy of CD301-CAR NK92 cells against osteosarcoma.
- To assess the combination therapy of CD301-CAR NK92 cells and TIGIT inhibition.
Main Methods:
- Staining of primary osteosarcoma tissues with recombinant CD301 (MGL, CLEC10A).
- In vitro evaluation of CD301-CAR NK92 cell-mediated cytotoxicity against osteosarcoma cells.
- Assays for NK cell degranulation and cytokine release.
- Combination therapy studies involving CD301-CAR and anti-TIGIT antibodies.
Main Results:
- CD301 ligands were expressed in a subset (26%) of primary osteosarcoma tumors.
- CD301-CAR NK92 cells demonstrated recognition and elimination of osteosarcoma cells in vitro.
- Cytotoxic activity correlated with enhanced degranulation and cytokine release.
- Combination with TIGIT inhibition yielded additional therapeutic benefits.
Conclusions:
- CD301 ligands represent novel target structures for lectin-based immunotherapy in osteosarcoma.
- CD301-CAR NK92 cells show therapeutic potential against osteosarcoma.
- Combined targeting of CD301 and TIGIT may enhance treatment outcomes for osteosarcoma patients.
Related Concept Videos
01:05Proteoglycans
3.9K
Glycans, a class of complex heterogeneous molecules, can be covalently attached to proteins to form glycosylated proteins that regulate various physiological and pathological processes. Glycosylated proteins or glycoproteins comprise N-linked and O-linked oligosaccharides. O-glycosylation is the most common type of protein glycosylation. Here, glycans attach to the oxygen atom of the hydroxyl groups of Serine or Threonine residues. O-linked glycosylation occurs later in protein processing,...
3.9K
01:27Tumor Immunotherapy
515
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
515